Last close As at 05/08/2026
GBP0.03
— 0.00 (0.00%)
Market capitalisation
GBP5m
Research: TMT
Nanoco’s planned raise of £8.6m (subject to approval) should remove a major constraint on the company’s ability to execute its strategy. The balance sheet strength should support customer negotiations at both the developmental level and as it moves towards volume shipments. The ability to attract and retain good staff and the ability to monetise and protect its IP both in display and beyond should also benefit, albeit at the expense of 20% dilution.
Written by
Nanoco Group |
Removal of elephant in the room |
Fund-raise |
Tech hardware & equipment |
6 October 2017 |
Share price performance
Business description
Analysts
Nanoco Group is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||
Nanoco’s planned raise of £8.6m (subject to approval) should remove a major constraint on the company’s ability to execute its strategy. The balance sheet strength should support customer negotiations at both the developmental level and as it moves towards volume shipments. The ability to attract and retain good staff and the ability to monetise and protect its IP both in display and beyond should also benefit, albeit at the expense of 20% dilution.
Year |
Revenue (£m) |
PBT* |
EPS* |
DPS |
EV/sales |
P/E |
07/16 |
0.5 |
(12.3) |
(5.2) |
0.0 |
119.6 |
N/A |
07/17e |
1.6 |
(9.8) |
(4.1) |
0.0 |
37.4 |
N/A |
07/18e |
4.5 |
(7.1) |
(3.0) |
0.0 |
13.3 |
N/A |
Note: *PBT and EPS are normalised and diluted, excluding intangible amortisation, exceptional items and share-based payments.
Subject to shareholder approval, Nanoco has successfully raised £8.6m. The company will issue 47.7m new shares at 18p each, a discount of c 35.7%, which will represent 16.7% of the enlarged share capital.
The strengthening of the balance sheet should help the company in a number of ways. Firstly, it should significantly strengthen customer confidence, supporting engagement from the R&D level through to volume orders. Nanoco’s ability to attract and retain skilled employees will also benefit, key to enabling the company to exploit its lead in cadmium-free quantum dots in display and to develop earlier-stage projects in areas such as medical imaging. With its monthly cost base running at £670k – somewhat below our current estimate of £790k – Nanoco should have enough cash to last beyond July 2019, even in the absence of substantial volume orders. We leave our forecasts unchanged pending shareholder approval.
|
Disclaimer
|
|
Disclaimer
|
Research: Healthcare
New financing from the European Investment Bank (EIB) of up to €35m will support NanoTherm’s European rollout for treatment of both brain and prostate cancer patients. In the US, a second clinical treatment site has been established in Texas and the IDE approval process with the FDA continues. In H117, the net loss for the period was €3.0m (H116: €3.2), while gross cash as of 30 June 2017 stood at €7.7m but does not include any drawdowns from the EIB loan, which was signed post period.